A Review of Sodium-Glucose Cotransporter 2 Inhibitor’s Clinical Efficacy in Heart Failure With Preserved Ejection Fraction

TL;DR

This paper reviews how SGLT2 inhibitors may help manage heart failure with preserved ejection fraction, offering new treatment insights.

Contribution

The paper provides a comprehensive review of SGLT2 inhibitors' clinical use in HFpEF, highlighting their potential as a novel treatment.

Findings

SGLT2 inhibitors show promise in reducing hospitalizations for HFpEF patients.

The mechanisms of SGLT2 inhibitors include multiple cardioprotective effects.

Current therapies for HFpEF remain suboptimal, but SGLT2 inhibitors offer potential improvements.

Abstract

Heart failure (HF) poses a significant healthcare burden, with distinct subtypes based on ventricular function. HF with preserved ejection fraction (HFpEF) presents unique epidemiological and mechanistic features compared to HF with reduced ejection fraction (HFrEF). The pathophysiology of HFpEF is complex and involves multiple factors. Current pharmacological therapies for HFpEF remain suboptimal, with inconsistent mortality outcomes observed despite improvements in symptoms and quality of life. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as promising agents in HF management and hospitalizations, particularly in HFpEF patients. The cardioprotective mechanisms of SGLT2 inhibitors are multifactorial. In this article, we performed a comprehensive review of SGLT2 inhibitor use in HFpEF and discussed the implications in the management of HF.